Hillhurst Biopharmaceuticals receives funding for development of HBI-002 for the treatment of diabetic retinopathy
SAN DIEGO, CA (September 14, 2023) Hillhurst Biopharmaceuticals, ...
Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002
SAN DIEGO, CA (April 23, 2021) Hillhurst Biopharmaceuticals, Inc. ...
Hillhurst Biopharmaceuticals Receives Funding For Development Of HBI-002 For Treatment of Ulcerative Colitis
SAN DIEGO, CA (March 25, 2021) Hillhurst Biopharmaceuticals, Inc., ...
Hillhurst biopharmaceuticals receives funding for development of HBI-002 for prevention of anthracyline-related cardiotoxicity in cancer patients
SAN DIEGO, CA (August 19, 2020) Hillhurst Biopharmaceuticals, ...
Hillhurst Biopharmaceuticals Receives Phase 2 SBIR Funding For Clinical Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises in Sickle Cell Disease.
SAN DIEGO, CA (Nov. 28, 2018) Hillhurst Biopharmaceuticals, Inc., ...
Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Delayed Graft Function In Kidney Transplantation
SAN DIEGO, CA (June 14, 2017) Hillhurst Biopharmaceuticals, Inc., ...
Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises In Sickle Cell Disease
SAN DIEGO, CA (May 24, 2016) – Hillhurst Biopharmaceuticals, ...
Hillhurst Biopharmaceuticals Receives SBIR Funding for Development of HBI-002 as a Cytoprotective Therapeutic in Acute Cerebral Injury
SAN DIEGO, CA (December 1, 2015) – Hillhurst Biopharmaceuticals, ...